PROX1/α-SMA correlated with colorectal cancer progression, poor outcomes and therapeutic resistance

9 Feb 2024
PROX1/α-SMA correlated with colorectal cancer progression, poor outcomes and therapeutic resistance

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 2, entitled, “PROX1 interaction with α-SMA-rich cancer-associated fibroblasts facilitates colorectal cancer progression and correlates with poor clinical outcomes and therapeutic resistance.”

The tumour microenvironment (TME) plays a vital role in tumour progression through intricate molecular interactions.

Cancer-associated fibroblasts (CAFs), notably those expressing alpha-smooth muscle actin (α-SMA) or myofibroblasts, are instrumental in this context and correlate with unfavourable outcomes in colorectal cancer (CRC).

While several transcription factors influence TME, the exact regulator causing CAF dysregulation in CRC remains elusive.

Prospero Homeobox 1 (PROX1) stands out, as its inhibition reduces α-SMA-rich CAF activity. However, the therapeutic role of PROX1 is debated due to inconsistent study findings.

In this new study, researchers Shiue-Wei Lai, Yi-Chiao Cheng, Kee-Thai Kiu, Min-Hsuan Yen, Ying-Wei Chen, Vijesh Kumar Yadav, Chi-Tai Yeh, Kuang-Tai Kuo, and Tung-Cheng Chang from Taipei’s National Defense Medical Center, Taipei Medical University, Taipei Medical University Shuang-Ho Hospital, and National Taitung University used the ULCAN portal and noted an elevated PROX1 level in advanced colon adenocarcinoma, linking to a poor prognosis.

Their assays determined the impact of PROX1 overexpression on CRC cell properties, while co-culture experiments spotlighted the PROX1-CAF relationship. Molecular expressions were validated by qRT-PCR and Western blots, with in vivo studies further solidifying the observations.

“Our study emphasised the connection between PROX1 and α-SMA in CAFs.”

Elevated PROX1 in CRC samples correlated with increased α-SMA in tumours. PROX1 modulation influenced the behaviour of specific CRC cells, with its overexpression fostering invasiveness.

Kaplan-Meier evaluations demonstrated a link between PROX1 or α-SMA and survival outcomes.

Consequently, PROX1, alone or with α-SMA, emerges as a CRC prognostic marker. Co-culture and animal experiments further highlighted this relationship.

PROX1 appears crucial in modulating CRC behaviour and therapeutic resistance within the TME by influencing CAFs, signifying the combined PROX1/α-SMA gene as a potential CRC prognostic marker.

The concept of developing inhibitors targeting this gene set emerges as a prospective therapeutic strategy.

However, this study is bound by limitations, including potential challenges in clinical translation, a focused exploration on PROX1/α-SMA potentially overlooking other significant molecular contributors, and the preliminary nature of the inhibitor development proposition.

“As we advance in this field, the development and clinical validation of small-molecule inhibitors targeting PROX1/α-SMA become imperative, paving the way to refine and optimise CRC therapeutic interventions.”

Source: Impact Journals